ARG 201

Drug Profile

ARG 201

Alternative Names: ARG201; Bovine type 1 collagen - arGentis

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Tennessee
  • Developer arGentis Pharmaceuticals
  • Class Extracellular matrix proteins; Fibrillar collagens
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Systemic scleroderma

Most Recent Events

  • 06 Aug 2015 Phase-II development for scleroderma is ongoing
  • 17 Feb 2009 ARG 201 receives Orphan Drug Status for Systemic scleroderma in the EU
  • 01 Jul 2008 Final efficacy data from a phase II trial in Systemic scleroderma released by arGentis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top